arrow
S

Suguru Fukuhara

Department of Hematology
H指数:19
被引数:1,009

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world outcomes of chimeric antigen receptor T-cell therapy with pembrolizumab as holding and/or bridging therapy in relapsed/refractory primary mediastinal large B-cell lymphoma

嵌合抗原受体T细胞疗法联合帕博利珠单抗作为维持和/或桥接疗法在复发/难治性原发纵隔大B细胞淋巴瘤中的真实世界疗效

2026-04-130
PRE
Comparison of gene fusion detection algorithms reveals frequently overlooked driver fusions in hematologic malignancies

基因融合检测算法的比较揭示了血液恶性肿瘤中常被忽视的驱动融合。

2026-04-040
OAAI
Clonal analysis of a case with fluid overload-associated large B-cell lymphoma evolving from primary large B-cell lymphoma of the central nervous system

一例液体超负荷相关的大B细胞淋巴瘤(由中枢神经系统原发性大B细胞淋巴瘤演变而来)的克隆分析

2026-03-110
OAAI
T-cell fitness, metabolic tumor volume, and serum LDH levels are associated with response to axicabtagene ciloleucel

T细胞活力、代谢肿瘤体积和血清LDH水平与axicabtagene ciloleucel的反应相关

2026-01-010
PRE
Correlation with CD79B expression and clinicopathological parameters including cell of origin, CD79A and CD19 expression, and CD79B mutation in diffuse large B-cell lymphoma

与CD79B表达及临床病理参数(包括起源细胞、CD79A和CD19表达以及CD79B突变)在弥漫性大B细胞淋巴瘤中的相关性

2025-06-140
PRE
Whole exome sequencing analysis of a patient with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions with ETV6::LYN fusion gene

嗜酸性粒细胞增多和酪氨酸激酶基因与ETV6::LYN融合基因融合的骨髓/淋巴肿瘤患者的全外显子组测序分析

2024-12-200
PRE
A first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors (CTX-712-CL-01 study): Efficacy and safety in a hematologic malignancies cohort
2024-04-050
PRE
Clinicopathological and genetic features of limited-stage diffuse large B-cell lymphoma with late relapse: targeted sequencing analysis of gene alterations in the initial and late relapsed tumors
2020-03-262
OAAI